Department of Nuclear Medicine, University Hospital Ghent, De Pintelaan, Gent, Belgium.
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2188-93. doi: 10.1007/s00259-010-1496-z. Epub 2010 Jun 11.
To give an up-to-date overview of the potential clinical utility of (18)F-labelled choline derivatives for tumour imaging with positron emission tomography.
A PubMed search for (18)F-labelled choline analogues was performed. Review articles and reference lists were used to supplement the search findings.
(18)F-labelled choline analogues have been investigated as oncological PET probes for many types of cancer on the basis of enhanced cell proliferation. To date, studies have focused on the evaluation of prostate cancer. Available studies have provided preliminary results for detecting local and metastatic disease. Experience with (18)F-fluorocholine PET in other tumour types, including brain and liver tumours, is still limited. In the brain, excellent discrimination between tumour and normal tissue can be achieved due to the low physiological uptake of (18)F-fluorocholine. In the liver, in which there is a moderate to high degree of physiological uptake in normal tissue, malignancy discrimination may be more challenging.
PET/CT with (18)F-fluorocholine can be used to detect (recurrent) local prostate cancer, but seems to have limited value for T (tumour) and N (nodal) staging. In patients presenting with recurrent biochemical prostate cancer, it is a suitable single-step examination with the ability to exclude distant metastases when local salvage treatment is intended. In the brain, high-grade gliomas, metastases and benign lesions can be distinguished on the basis of (18)F-fluorocholine uptake. Moreover, PET imaging is able to differentiate between radiation-induced injury and tumour recurrence. In the liver, (18)F-fluorocholine PET/CT seems promising for the detection of hepatocellular carcinoma.
提供（18）F 标记胆碱衍生物在正电子发射断层扫描（PET）肿瘤成像中潜在临床应用的最新概述。
在 PubMed 上进行了（18）F 标记胆碱类似物的搜索。综述文章和参考文献用于补充搜索结果。
（18）F 标记胆碱类似物已被研究作为多种癌症的肿瘤 PET 探针，基于细胞增殖增强。迄今为止，研究主要集中在前列腺癌的评估上。现有研究为检测局部和转移性疾病提供了初步结果。在其他肿瘤类型（包括脑肿瘤和肝肿瘤）中使用（18）F-氟代胆碱 PET 的经验仍然有限。在脑内，由于（18）F-氟代胆碱的生理摄取量低，肿瘤与正常组织之间可以实现极好的区分。在肝脏中，由于正常组织中存在中度至高度的生理摄取，因此恶性肿瘤的鉴别可能更具挑战性。
（18）F-氟代胆碱 PET/CT 可用于检测（复发性）局部前列腺癌，但在 T（肿瘤）和 N（淋巴结）分期方面似乎价值有限。对于出现生化复发前列腺癌的患者，当打算进行局部挽救治疗时，这是一种合适的单一检查方法，能够排除远处转移。在脑内，高级别胶质瘤、转移瘤和良性病变可以根据（18）F-氟代胆碱的摄取来区分。此外，PET 成像能够区分放射性损伤和肿瘤复发。在肝脏中，（18）F-氟代胆碱 PET/CT 似乎有望用于检测肝细胞癌。
